Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (531-540 of 755) with videos related to

Pageof 76
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Disability and Rehabilitation|March 20, 2020
Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique studySami Harb, Julie Cumin, Danielle B Rice, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Pageof 76

Showing results (531-540 of 755) with videos related to

Sort By:
Pageof 76
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung diseaseElizabeth R Volkmann, Rajeev Saggar, Dinesh Khanna, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Disability and Rehabilitation|March 20, 2020
Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique studySami Harb, Julie Cumin, Danielle B Rice, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Pageof 76